Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.

Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A, Hernandez AF, Gibson CM; APEX Investigators..

N Engl J Med. 2016 Aug 11;375(6):534-44. doi: 10.1056/NEJMoa1601747.

2.

Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELD-AF and treated with vitamin K antagonists.

Fitzmaurice DA, Accetta G, Haas S, Kayani G, Lucas Luciardi H, Misselwitz F, Pieper K, Ten Cate H, Turpie AG, Kakkar AK; GARFIELD-AF Investigators..

Br J Haematol. 2016 Aug;174(4):610-23. doi: 10.1111/bjh.14084.

PMID:
27071942
3.

1-R-2-([1,2,4]Triazolo[1,5-c]quinazoline-2-ylthio)etanon(ol)s: Synthesis, Bioluminescence Inhibition, Molecular Docking Studies, Antibacterial and Antifungal Activities.

Antypenko LM, Kovalenko SI, Karpenko OV, Katsev AM, Novikov VP, Fedyunina NS.

Curr Comput Aided Drug Des. 2016;12(1):29-41.

PMID:
27012316
4.

Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators.; ROCKET AF Steering Committee Investigators..

J Am Heart Assoc. 2016 Mar 8;5(3):e002197. doi: 10.1161/JAHA.115.002197.

5.

1-R-2-([1,2,4]Triazolo[1,5-c]quinazoline-2-ylthio)etanon(ol)s: synthesis, bioluminescence inhibition, molecular docking studies, antibacterial and antifungal activity.

Antypenko LM, Kovalenko SI, Karpenko OV, Katsev AM, Novikov VP, Fedyunina NS.

Curr Comput Aided Drug Des. 2016 Jan 26. [Epub ahead of print]

PMID:
26813534
6.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators..

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

7.

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators..

N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489.

8.

A synopsis of original research projects published in scientific database in the Russian Federation.

Smirnova D, Pavlichenko A, Karpenko O, Schmeleva L, Morozov P.

Asian J Psychiatr. 2015 Jun;15:93-6. doi: 10.1016/j.ajp.2015.05.004. Review.

PMID:
26022056
9.

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo.

Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators..

Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002.

PMID:
25965710
10.

Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.

Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ, Ponikowski P, Anker SD; WARCEF Investigators..

Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725.

11.

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators..

N Engl J Med. 2015 Apr 16;372(16):1489-99. doi: 10.1056/NEJMoa1501031.

12.

Long-term use of ticagrelor in patients with prior myocardial infarction.

Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators..

N Engl J Med. 2015 May 7;372(19):1791-800. doi: 10.1056/NEJMoa1500857.

13.

Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.

Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP, Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A, Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators..

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/CIRCOUTCOMES.114.001556.

14.

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.

Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, Chaudhari U, Colhoun HM; ODYSSEY COMBO II Investigators..

Eur Heart J. 2015 May 14;36(19):1186-94. doi: 10.1093/eurheartj/ehv028.

15.

Synthesis and evaluation of anticancer activity of 5-ylidene-4- aminothiazol-2(5H)-one derivatives.

Kaminskyy D, Subtel'na I, Zimenkovsky B, Karpenko O, Gzella A, Lesyk R.

Med Chem. 2015;11(6):517-30.

PMID:
25669320
16.

Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Graham S, Ye S, Qian M, Sanford AR, Di Tullio MR, Sacco RL, Mann DL, Levin B, Pullicino PM, Freudenberger RS, Teerlink JR, Mohr JP, Labovitz AJ, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Thompson JL, Homma S; WARCEF Investigators..

PLoS One. 2014 Nov 26;9(11):e113447. doi: 10.1371/journal.pone.0113447.

17.

Interaction between digoxin and dronedarone in the PALLAS trial.

Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators..

Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1019-25. doi: 10.1161/CIRCEP.114.002046.

18.

Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: a potentially useful tool in differential diagnosis.

Wallace DJ, Gavin IM, Karpenko O, Barkhordar F, Gillis BS.

Rheumatol Int. 2015 Jun;35(6):991-6. doi: 10.1007/s00296-014-3172-2.

19.

Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.

Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR, Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF Investigators..

Cerebrovasc Dis. 2014;38(3):176-81. doi: 10.1159/000365502.

20.

Ivabradine in stable coronary artery disease without clinical heart failure.

Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R; SIGNIFY Investigators..

N Engl J Med. 2014 Sep 18;371(12):1091-9. doi: 10.1056/NEJMoa1406430.

Items per page

Supplemental Content

Loading ...
Support Center